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Abstract
Increasing evidence suggests that mucosally targeted vaccines will enhance local humoral and cellular responses whilst still
eliciting systemic immunity. We therefore investigated the capacity of nasal, sublingual or vaginal delivery of DNA-PEI
polyplexes to prime immune responses prior to mucosal protein boost vaccination. Using a plasmid expressing the model
antigen HIV CN54gp140 we show that each of these mucosal surfaces were permissive for DNA priming and production of
antigen-specific antibody responses. The elicitation of systemic immune responses using nasally delivered polyplexed DNA
followed by recombinant protein boost vaccination was equivalent to a systemic prime-boost regimen, but the mucosally
applied modality had the advantage in that significant levels of antigen-specific IgA were detected in vaginal mucosal
secretions. Moreover, mucosal vaccination elicited both local and systemic antigen-specific IgG+ and IgA+ antibody
secreting cells. Finally, using an Influenza challenge model we found that a nasal or sublingual, but not vaginal, DNA prime/
protein boost regimen protected against infectious challenge. These data demonstrate that mucosally applied plasmid DNA
complexed to PEI followed by a mucosal protein boost generates sufficient antigen-specific humoral antibody production
to protect from mucosal viral challenge.
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Introduction
Mucosal surfaces act as the first line of defence against a
plethora of different opportunistic pathogens including infectious
agents of the respiratory, gastrointestinal and the genitourinary
tracts [1]. Apart from a few licensed mucosally applied vaccines,
the vast majority of current vaccination strategies employ systemic
routes of immunisation, thought to be less effective in generating
protective local responses at mucosal surfaces [1]. In contrast,
mucosal vaccination has been shown to effect local and systemic
immune responses. This is because the site of antigen entry can
play a part in the T and B cell receptor imprinting and thus their
homing capabilities [2,3]. Furthermore, the delivery site of
mucosally-applied vaccine formulations has been shown to impact
immune outcome [4]. Despite this, a major impediment to the
development of vaccines targeting mucosal surfaces is that the
direct application of antigens to mucosal surfaces results in weak
immune responses [5]. Hence newer vaccine delivery technologies,
capable of utilising or circumventing the formidable mucosal
barrier and initiating the desired immune responses, have the
potential to drive the field of mucosal vaccination forward.
Currently, most clinically approved vaccines rely on the
production of protective humoral responses. However genetic
based vaccines have been shown to induce both the cellular and
humoral arms of immunity [6]. To do this, DNA vaccines utilise
the recipients host cell machinery to manufacture the encoded
transgene product for major histocompatibility complex (MHC)
class I and II presentation [7]. This process results in the
generation of endogenous vaccinating proteins that are confor-
mationally similar to the natively expressed form of the antigen
and with the appropriate post-translational modifications [8,9].
Despite this, the delivery of vaccinating DNA in vivo has resulted in
limited transgene expression [10], normally in the nanogram
range [11] leading to reduced immunogenicity in larger animal
models or human clinical trials [8]. To circumvent these short
fallings, DNA vaccinations have been incorporated into prime-
boost vaccination regimens. Critically, the use of DNA prime
vaccinations in a number of prime-boost studies has been shown to
broaden both the pathogen-specific humoral and cellular immune
responses, an outcome that is likely to enhance the efficacy of any
prophylactic vaccine [8,12,13].
Within this study we set out to improve upon current
prophylactic mucosal vaccine regimens by applying a vaccine
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prime topically to the mucosa using a DNA preparation
incorporating polyethyleneimine (PEI). Condensation of plasmid
DNA with cationic PEI has previously shown great potential in the
vaccine delivery field by significantly increasing transfection rates
and immune responses [14–16]. Here we sought to investigate the
potential of a DNA prime – protein boost vaccination strategy to
elicit humoral antibody responses when applied to three different
mucosal surfaces. Specifically we compared the immunogenicity of
nasal, vaginal and sublingual routes of DNA (HIV-1 gp140)
polyplex prime vaccination followed by protein boost vaccination
with recombinant HIV-1 gp140. We show that plasmid DNA
followed with recombinant protein, delivered via the nasal and
sublingual routes, elicited strong serum and mucosal antigen-
specific antibody responses and significant numbers of antigen-
specific IgG+ and IgA+ antibody secreting cells in the spleen.
However, vaginal vaccination elicited serum and mucosal antigen-
specific IgA in the absence of detectable specific IgG while also
increasing numbers of locally resident specific IgA+ B cells. In
addition, we show that the IgG antibody bias is influenced by the
route of DNA mucosal priming where sublingual immunisation
displayed a higher tendency or bias toward an IgG1 response
while nasal immunisation generated a more balanced response.
Finally, we demonstrate that intranasally applied DNA prime
immunisation and recombinant protein boost vaccination is
sufficient to protect mice from influenza infection.
Materials and Methods
Protein, DNA Plasmid and Complex Formation
The HIV-1 CN54-gp140 clade C/B (codon optimised) was
provided by Roger Tatoud, UK HVC, Imperial College London.
The ZM96-gp140 clade C plasmid was provided by Simon Jeffs,
Imperial College London. The Influenza A virus (A/Aichi/2/
1968(H3N2)) hemagglutinin (X31-HA) gene (GenBank accession
no. CY121117.1) was synthesised and codon optimised for
maximal expression in mice using the OptimumGeneTM algo-
rithm (GenScript, CN). The X31-HA gene sequence was altered
in accordance to the work published by Wei et al., 2009 [17],
where the HA gene was modified at the C terminus through the
addition of the bacteriophage T4 fibritin foldon trimerization
sequence. The X31-HA insert was cloned into the pmaxFPTM-
Red C vector (Lonza, UK). Large scale plasmid production was
carried out using an Endo free Gigaprep kit (Qiagen, UK). The
plasmids were then complexed to InVivoJet PEI (PolyPlus
Transfection, Fr) using an N/P ratio of 8 as per the manufactur-
er’s instructions. Homologous recombinant CN54-gp140 protein
was purchased from Polymun (Austria) and the H3N2 A/Aichi/2/
1968 was purchased from Sino Biological Inc., (China).
Immunisation, Sampling and Infections
Female BALB/c mice (Harlan, UK), 6–8 weeks old, were
placed into groups of n = 8 or n= 6 and housed in a fully
acclimatised room. All animals were handled and procedures
performed in accordance with the terms of a project licence
granted under the UK Home Office Animals (Scientific Proce-
dures) Act 1986. One week prior to the commencement of the
study and every three weeks thereafter, mice receiving vaginal
immunisations were treated subcutaneously with 2 mg medroxy-
progesterone (Pharmacia, UK) to synchronise the menstrual cycle
and thin the vaginal epithelium. Food and water were supplied ad
libitum. For initial studies, mice received DNA with (+PEI) or
without (-PEI) to determine the utility of cation complex.
Subsequently, all mice received three 20 mg/15 ml doses of
CN54-gp140 DNA-PEI formulation vaginally (I.Vag), nasally
(IN) or sublingually (SL) followed by three 20 mg CN54-gp140
protein boosts by the same route. Intramuscular (IM) positive
controls received three 20 mg/50 ml doses of naked plasmid DNA
into the right quadriceps followed by three 20 mg/50 ml gp140
protein boosts in the same muscle. For HA vaccine studies, 20 mg
of HA DNA polyplex or protein was delivered in a 30 ml volume
and administered via the intranasal, sublingual and vaginal routes.
Tail bleeds were collected weekly without anti-coagulant and
centrifuged in a Heraeus Biofuge pico (Fisher, UK) at 1000 g for
20 min. The serum was harvested and transferred into fresh
0.5 ml micro-centrifuge tubes (Starlab, UK), and stored at 220uC
until antibody titres were determined by ELISA. Vaginal lavage
using three 25 ml washes/mouse with PBS, that were then pooled,
was carried out weekly. Lavage samples were incubated for 30 min
with 4 ml protease inhibitor (Roche Diagnostics, Germany) before
centrifuging at 1000 g for 10 min. The fluid supernatant from
these treated samples were then transferred into fresh 0.5 ml
micro-centrifuge tubes, and stored at 220uC until antibody titres
were determined by ELISA. For infections mice were lightly
anesthetised using isoflurane before nasal instillation of 100 ml of
5HAU Influenza X-31 (H3N2). Mice weights were monitored
daily for signs of infection.
Antibody ELISA
An in-house developed, quantitative, CN54gp140 and HA
antigen-specific antibody ELISA protocol was followed. Briefly,
ELISA plates were coated with 100 ml per well of 5 mg/ml gp140
antigen or purified recombinant HA diluted in sterile PBS. Plates
were then covered with a plate seal and incubated overnight at
4uC. The plates were then washed four times by PBST (Invitrogen,
UK) and blocked by adding 200 ul per well of assay buffer (1%
BSA in 0.05% PBST). The plates were then sealed and incubated
for 1 hour at 37uC. After the incubation, the plates are washed 4
times with 250 ml of PBST. A 50 ml volume of antibody sample
from serum diluted 1:1000, 1:10,000 and 1:50,000 in sample
diluent were then added to the plate in triplicate. Plates were than
resealed and incubated for 1 hour at 37uC. The plates were
washed 4 times with 250 ml of PBST per well, before the addition
of a 1:4000 dilution in sample diluent of 100 ml/well of either anti-
mouse IgG-HRP, anti-mouse IgG1-HRP, anti-mouse IgG2a-HRP
or IgA-HRP (Southern Biotech) to detect antigen reactive
antibody. Plates were incubated for 1 hour at 37uC before 4
washes with 250 ml PBST. Plates were developed using the
addition of 100 ml/well TMB and the reaction stopped after 5 min
using Stop solution (Insight Biotechnologies, UK). Standards on
the plate consisted of coating with 100 ml anti-mouse Kappa
(1:3200) and Lambda (1:3200) light chain (Serotec, UK), blocking
as before and then adding 50 ml of highly purified polyclonal
mouse IgG, IgG1, IgG2a or IgA (Southern Biotech, UK) in a 1:3
dilution in sample diluent down the plate starting at 200 ng/ml.
The rest of the process was the same as for the samples where the
secondary antibodies were incubated for 1 hour, washed, the
reaction developed with TMB and stopped with Stop solution
(Insight Biotechnologies, UK). Mucosal samples were assayed in
duplicates using a 1:10, 1:50 and 1:250 dilution. For mucosal IgA,
biotinylated-IgA (1:4000) was used followed by one hour
incubation with Streptavidin-HRP (R&D systems). The absor-
bance was read on a KC4 Spectrophotometer at 450 nm (Bio-Tek
Industries, Inc).
Tissue Processing for ELISPOT Assay
To assess IgG, IgA B cell and IFN-c T cell responses,
lymphocyte cultures from spleens or vaginas of immunised and
control mice were made. Briefly, mice were euthanised, and their
Mucosal DNA Vaccine Delivery and Immunogenicity
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spleens removed aseptically and placed into individual 20 ml
universal tubes (Greiner, UK) containing 2 ml RPMI 1640
medium (Sigma Aldrich Ltd, UK). The vaginas were then
removed and pooled together according to their groups. The
spleens were placed into Petri dishes and single cell suspensions
made by disrupting the spleens. This was achieved by grinding the
spleens through a 70 mm Nylon Cell Strainers (BD Falcon, UK)
using a syringe plunger. The cell suspensions were then
centrifuged at 350 g for 10 min. The supernatants were decanted
and the pelleted cells re-suspended in ACK lysis buffer for 5 min
(Gibco, UK). The cell suspensions were vortexed and centrifuged
at 350 g for 10 min. The pelleted cells were decanted and re-
suspended in 1 ml RPMI 1640 medium. This step was repeated
three times with the cells resuspended in complete RPMI and then
filtered through a 100 mm Filcon unit (BD Biosciences, UK). The
cells were counted using a hemocytometer. For the pooled vaginas
the RPMI media was decanted and the vaginas cut into small
pieces (262 mm) and mechanically disrupted using scalpels. The
pooled samples were then incubated with enzymatic digestion
solution containing Liberase DL (15 ug/ml, Roche) and DNase
(100 U/ml, Roche) in RPMI, for 45 min at 37uC. The digested
tissue was then placed in sterile 50 mm Medicon grinders before
being homogenised in a Medimachine (BD Biosciences, UK) for
2 min. Samples were visually inspected every 30 s to prevent intact
material remaining on the blades. The homogenate was extracted
and the samples filtered through a 100 mm Filcon unit before cell
counting.
Antigen-specific ELISPOT
Antigen-specific IgG, and IgA spleen and vaginal ELISPOT
assays were carried out using a commercially available ELISPOT
kit with associated detection antibodies and reagents (MABTECH,
UK) as per the manufacturer’s instructions. Briefly, plates were
activated using two washes of 50 ml/well of 70% ethanol followed
by five rinses with 200 ml/well sterile water. The plates were then
coated using 5 mg/ml gp140 antigen in PBS overnight at 4uC. The
next day, plates were washed five times in sterile PBS and blocked
for 30 minutes using complete RPMI. The media was removed
from the plate, the cells at a concentration of 56106 cells/ml
added, and the plates incubated for 16 hours at 37uC
supplemented with 5% CO2. The next day, plates were washed
five times in PBS before a two hour incubation with 100 ml/well of
1 mg/ml of the supplied biotinylated anti-mouse IgG. The plates
were washed five times before adding a 1/1000 dilution of the
supplied Streptavidin-ALP for one hour. Samples were developed
using the kits BCIP/NBT-plus reagent. For antigen-specific IgA
ELISPOT samples, a biotinylated anti-IgA was used. For
assessment of IFN-c T cell responses, a similar protocol was
followed except 15 mg/ml coating antibody (AN18) was used to
coat the plates while 5 mg/ml of PHA polyclonal activator served
as the positive controls for each sample. Cell cultured in complete
RPMI in the absence of stimuli served to demonstrate background
levels of activation. To detect spots, biotinylated anti-IFN-c
antibody was added at 1 mg/ml for 2 hours before washing and
incubating with Streptavidin-HRP for 1 hour. The plate was
washed as before and 100 ml/well TMB substrate added. ELI-
SPOT plates were read using an AID ELISPOT reader ELR03
(Autoimmun Diagnostika GmbH, Ger) and the AID ELISPOT
READER 4 software (Autoimmun Diagnostika GmbH, Ger). The
background of the IgG, IgA and IFN-c ELISPOT assays were
calculated as twice the mean number of SFU/million cells in the
un-stimulated samples. After subtracting the background, samples
yielding 50 SFU/million or more were regarded as positive.
Statistical Analysis
Statistical analysis of the data was carried out using a Mann–
Whitney, U-test or Wilcoxon non-parametric paired T test using
GraphPad PRISM software.
Results
A DNA Priming Strategy Delivered via the Nasal Route is
Superior to Intramuscular Vaccination for the Generation
of Mucosal IgA
Initial experiments were performed to assess the ability of a
trimeric gp140 DNA polyplex vaccine formulation to prime
mucosal immune responses after topical nasal (IN) application.
This was undertaken to determine whether mucosal priming with
a gp140 expressing plasmid could be boosted by CN54-gp140
protein applied in the absence of adjuvant by the same route
(Fig. 1). A single DNA prime of 20 mg of gp140 expressing DNA
was administered either alone (-PEI) or complexed to PEI (+PEI),
followed by three fortnightly CN54-gp140 protein boost vaccina-
tions (Fig. S1). After the initial DNA prime and protein boost
immunisations, no detectable antigen-specific IgG (Fig. 1a) or IgA
(Fig. 1b) was recorded in serum samples. However, after a second
protein boost vaccination, elevated antibody levels were detected
for both the IN prime(+PEI)/boost and IM prime(-PEI)/boost
groups. A third and final protein boost vaccination generated a
peak antigen-specific IgG concentration of 664 ug/ml [IN
prime(+PEI)/boost] and 648 ug/ml [IM prime(-PEI)/boost] and
a peak specific IgA concentration of 1.51 ug/ml [IN prime(+PEI)/
boost] and 2.05 ug/ml [IM prime(-PEI)/boost]. No specific
antibody responses were detected after IN DNA(-PEI) prime/
boost vaccination or IN protein vaccination alone indicating an
important role for PEI for successful DNA delivery to mucosal
surfaces and the inability of antigen alone to prime immune
responses. At week 0, none of the treatment groups exceeded the
baseline threshold for mucosal antigen-specific IgG or IgA
antibody positivity. For mucosal IgG and IgA, the values at week
0 were below 0.274 ng/ml and 0.091 ng/ml respectively. Both
the IN prime(+PEI)/boost and the IM prime(-PEI)/boost groups
generated antigen-specific mucosal IgG (774.56884, **p=0.0079
and 413.56837 ng/ml, **p=0.0097 respectively) and IgA
(382.26509 ng/ml, **p = 0.0097 and 20.13611, **p = 0.0097)
in the vaginal vault (Figs. 1c,d). Interestingly although both the
IM prime(-PEI)/boost and IN prime(+PEI)/boost strategies
generated similar antibody concentrations in the systemic com-
partment, the IN prime(+PEI)/boost regimen generated signifi-
cantly more specific IgA in the vaginal vault compared to the IM
prime(-PEI)/boost group (*p= 0.0317). Collectively this data
suggests that a single 20 mg DNA vaccination applied to mucosal
surfaces can prime for subsequent protein boost vaccinations but
may be relatively inefficient. Therefore we anticipate that multiple
DNA primes may be necessary to attain strong humoral responses
to a DNA priming candidate.
Impact of Administration Route on Systemic Humoral
Responses induced by Mucosal DNA Prime - Protein
Boost Regimens
Having shown that polyplex inoculation, encoding a model
trimeric gp140 transgene product, primed the nasal mucosa for
antigen-specific humoral responses, we used PEI for all further
mucosal applications of DNA complexes. We sought to determine
the impact of the route of administration on mucosal immune
priming. Here we delivered polyplexes to the IN, SL or I.Vag
mucosal surfaces and evaluated the induced humoral responses.
Mucosal DNA Vaccine Delivery and Immunogenicity
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Vaccinations consisted of either three doses of 20 mg CN54-gp140
DNA+PEI followed by three doses of 20 mg recombinant gp140
protein by the same route or recombinant gp140 protein in the
absence of any DNA priming vaccinations (Fig. S2). Priming of
CN54-gp140 specific IgG humoral immune responses was
observed in animals that received DNA via the IN and SL routes
(Figs. 2a, c). After the second DNA immunisation (week 3), IgG
responses were elevated above baseline levels in response to the IN
and SL regimens respectively. The SL group attained significant
levels of IgG during study week 7, one week after the third DNA
vaccination and both the IN and SL groups IgG responses
continued to rise until the end of the study (week 13). At week 13,
peak serum antigen-specific IgG concentrations of 1872 mg/ml
(***p = 0.0006) and 95.33 mg/ml (**p = 0.006) were attained after
IN and SL prime/boost vaccinations (Figs. 2a, c). As before, IN
immunisation with protein alone did not generate detectable
antigen-specific IgG responses. In addition, priming with 20 mg
DNA I.Vag followed by protein boost vaccination or by
vaccinating by protein alone did not generate any significant
serum antigen-specific IgG responses throughout the study
(Fig. 2b). All animals in the IN and SL CN54-gp140 DNA
prime - recombinant gp140 protein boost groups had a 100%
seroconversion rate while only 50% of the mice in the SL protein
alone group generated antigen-specific IgG responses.
At week 13, antigen-specific IgA was detected in serum after
both IN and SL prime boost vaccination regimens (Figs. 2d, f).
Elevated levels of serum IgA were detected in some animals after
the third DNA was delivered IN, but it was only after the second
protein boost that significant levels of IgA were detected (Figs. 2d).
After I.Vag inoculation, no significant serum IgA responses were
detected although some animals did produce low amounts of
antigen-specific IgA antibody (Figs. 2e). Peak serum antigen-
Figure 1. A single nasal DNA prime, triple protein boost regimen results in antigen-specific IgG and IgA in serum samples. Mice
(n = 5 per group) were vaccinated with either a single 20 mg DNA IN prime vaccination using ZM96-gp140 (+ PEI) followed by three 20 mg gp140
protein boost vaccinations (&), three 20 mg gp140 protein boost vaccinations (m), a single 20 mg DNA IM prime vaccination using ZM96-gp140 (2
PEI) followed by three 20 mg gp140 protein boost vaccinations (-&-) and finally a single 20 mg DNA IN prime vaccination using ZM96-gp140 (2 PEI)
followed by three 20 mg gp140 protein boost vaccinations (¤). Immunisations are indicated by vertical shaded lines. Antigen-specific serum IgG (a)
and IgA (b) were assessed by ELISA one week after each immunisation until study week 11. Vaginal mucosal lavage was performed to evaluate
antigen-specific IgG (c) and IgA (d) antibody responses during study week 11. Antibody results are expressed as geometric group means (mg/
ml+SEM). Statistical significance was assessed using Mann Whitney U test with **p,0.005; *p,0.05. Data are representative of two independent
experiments.
doi:10.1371/journal.pone.0067412.g001
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specific IgA concentrations were attained at study week 13 with
values of 53.6 mg/ml (***p = 0.0006), 10.19 mg/ml and 7.6 mg/ml
(*p = 0.0246) for the IN, I.Vag and SL routes respectively. All
animals in the IN group seroconverted while 85% of animals in
the SL group and 50% of the I.Vag group generated antigen-
specific IgA responses.
Figure 2. A triple DNA prime, triple protein boost regimen results in antigen-specific IgG and IgA in serum samples. Serum antigen-
specific IgG and IgA antibody responses (n = 8 mice per group) were assessed by ELISA one week after each immunisation until study week 13. Mice
were immunised every two weeks, with either three 20 mg CN54-gp140 polyplex prime vaccinations in a final 15 ml (IN, I.Vag and SL) volume,
followed by three 20 mg gp140 protein boost vaccinations, or with just three 20 mg gp140 protein vaccinations. Immunisations are indicated by
vertical shaded lines. Lines represent either protein immunisation (…) or DNA prime/boost vaccination groups (2). Antibody results are expressed as
geometric group means (ug/ml+SEM). Statistical significance was assessed using Mann Whitney U test with ***p,0.0005; **p,0.005; *p,0.05. Data
are representative of two independent experiments.
doi:10.1371/journal.pone.0067412.g002
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Intranasal DNA Immunisation is Equivalent to or Superior
to other Routes of Immunisation for Eliciting Systemic
Antibody
To date, parenteral immunisation, and in particular IM
vaccination, is the most common form of vaccine delivery. To
evaluate the mucosally delivered vaccine strategies against a
standard delivery method we compared the IN DNA prime –
protein boost vaccination regimen to the SL and I.Vag routes as
well as the more conventional intramuscular (IM) route. The IN
and IM regimens, both of which had 100% seroconversion rates
by the end of the study, generated virtually identical serum IgG
responses, which were found not to be statistically different
throughout the study (Fig. 3a). However, when comparing the IN
vaccination regimen with the SL route, significantly more serum
IgG was attained from week 5 to week 13 (*p = 0.0391). This was
also the case when comparing the IN and the I.Vag regimens
where IN vaccination produced significantly more IgG by week 5
and this was maintained until week 13 (*p = 0.0156). Statistically
higher concentrations of specific-IgA were recorded in sera when
comparing the IN treatment group and the I.Vag (**p = 0.0078),
SL (**p = 0.0078) or IM (**p = 0.0078) groups during study week
11 (Fig. 3b).
The IgG1/IgG2a Antibody Bias is Affected by the Site of
Topical Mucosal Application
To gain insight as to the differing effects of mucosally applied
DNA prime-protein boost vaccination regimens on the serum
antibody response, the IgG1/IgG2a ratios were assessed. As
expected, topical application of plasmid DNA followed by
recombinant protein boosts to either the IN or SL mucosae
generated antigen-specific serum IgG1 and IgG2a immune
responses. When analysed as a ratio, the IN inoculation group
generated an evenly distributed IgG1/IgG2a response (ra-
tio = 1.042) while the IM vaccination group generated higher
concentrations of IgG2a, indicative of a TH1 skew (ratio = 1.614).
Intriguingly, SL application of the regimen resulted in a clearly
biased IgG1 (or TH2 skew) antibody response with a ratio of 4.3
(Fig. 3c). No IgG responses were detected after I.Vag immuni-
sation therefore no assessment of IgG1 or IgG2a bias was
conducted.
Mucosal DNA Prime - Protein Boost Regimens Elicit
Specific Mucosal IgG and IgA
Protection against mucosally acquired viral infections is likely to
require the presence of local antigen-specific antibody to mediate
immunological exclusion, viral aggregation or neutralisation. To
examine vaccine mediated humoral responses at mucosal surfaces
we evaluated vaccine antigen-specific antibody responses following
DNA prime-protein boost in vaginal lavage. This allowed for a
repeated and non-terminal method to assess mucosal antibody
levels throughout the study. Vaccination resulted in antigen-
specific mucosal IgG being detected in vaginal lavage following IN
(666.4 ng/ml, ***p=0.0002), and SL (112 ng/ml, *p=0.049)
prime-boost applications while I.Vag vaccination did not generate
any significant levels of IgG (Fig. 4a). Here 100% and 87.5%
seroconversion rates were achieved for the IN and SL prime boost
vaccine groups. An IM prime-boost vaccination regime also
elicited antigen-specific IgG in vaginal lavage with 100% of the
vaccine recipients seroconverting (319.8 ng/ml, *p=0.0104).
Immunisation via the IN route elicited the greatest IgA response
(26.3 ng/ml, ***p=0.0002) with a 100% seroconverion rate while
the I.Vag route also generated significant IgA responses
(12.04 ng/ml, ***p=0.0002) and a 62.5% seroconversion rate.
Both SL and IM immunisation were ineffective at producing
antigen-specific IgA in mucosal vaginal lavage with 50% and
37.5% seroconverting respectively (Fig. 4b).
A DNA Prime - Protein Boost Regimen Generates Splenic
B Cell Responses via the Intranasal and Sublingual but
not the Intra-vaginal Route
We next examined the CN54-gp140 antigen-specific splenocyte
B cell responses using an antigen-specific ELISPOT. Vaccination
via the IN and SL routes generated significant numbers of IgG+
CN54-gp140 antigen-specific B cells, measured as spot forming
units (SFU) in the ELISPOT assay, relative to their unprimed
protein controls (71.8 SFU/million cells, ***p=0.0002 and
44.57 SFU/million cells, *p=0.0175 respectively) while no
responses were recorded for the DNA primed or unprimed
I.Vag inoculated animals (Fig. 4c). A similar response pattern for
antigen-specific IgA+ SFU was observed with both the IN
(144.5 SFU/million cells, ***p=0.0002) and SL (34.9 SFU/
million cells, *p=0.0379) regimens (Fig. 4d). Within this study,
we did not detect any systemic antigen-specific B cells in those
animals that had received the I.Vag inoculations, despite the
presence of statistically significant levels of CN54-gp140 specific
antibody within the vaginal mucosal secretions of this group
(Fig. 4d). A low number of CN54-gp140 specific IgA+ SFU were
recorded for the IM control route group (15.4 SFU/million cells),
while the same group generated 146.3 SFU/million antigen-
specific IgG+ cells (Figs. 4c,d).
Antigen-specific IgA+ SFU were also enumerated from pooled
single cell suspensions (n = 5) directly isolated from vaginal
mucosal tissue. After IN and I.Vag DNA prime-boost immunisa-
tion, a 2- and 6-fold increase respectively in the IgA+ CN54gp140-
specific B cell numbers were recorded when comparing them to
non-DNA primed animals. The lack of antigen-specific B cells in
the periphery but their presence within the vaginal tissue strongly
suggests local mucosal antibody production. This indicates that
both local priming and immunological linkage can be employed to
increase antigen-specific IgA responses within the vaginal mucosae
(Fig. 4e). Sublingual vaccination did not increase the numbers of
antigen-specific B cells within vaginal preparations.
Intranasal and Sublingual DNA Prime - Protein Boost
Regimens Provide Protection Against Influenza
Challenge
In the absence of a small animal model for HIV-1 infection, we
tested the protective efficacy of the vaccination regimens delivered
via different mucosal routes using a mucosally acquired influenza
infection-challenge model. Here the challenge was provided by the
murine adapted reassortment X-31 (H3N2) influenza strain. As
the delivery of multiple doses of this influenza HA protein via the
intranasal route can provide protection against infection (data not
shown), we altered the vaccination regimen to incorporate only a
single protein boost following a triple DNA prime (Fig. S3). In this
way, the effective priming of mucosal surfaces through the
application of DNA polyplexes could be evaluated. The applica-
tion of DNA resulted in detectable levels of antigen-specific IgG in
serum prior to IN protein boost vaccination (100% seroconver-
sion); and significantly elevated levels [5088 ng/ml (**p=0.0022)]
of specific IgG being detected after IN protein boost (Fig. 5a).
Although, elevated levels of serum IgG could be detected after SL
protein boost vaccination (Fig. 5c), this was found not to be
significant (66% seroconversion). I.Vag protein boost vaccination
did not lead to any detectable antigen-specific IgG in serum
(Fig. 5b). Interestingly, viral challenge resulted in protection in
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Figure 3. The route of prime/boost vaccination significantly alters serum antigen-specific antibody responses. Serum antigen-specific
IgG (a) and IgA (b) antibody (mg/ml+SEM) responses (n = 8 mice per group) were assessed by ELISA one week after each immunisation until study
week 13. The different prime-boost vaccination groups are compared to the IN prime-boost vaccine group for assessment of statistical significance
(Wilcoxon non-parametric paired t test). Serum antigen specific IgG1 and IgG2a concentrations (c) were assessed during study week 13. The IgG1 and
IgG2a ratios were derived by dividing the IgG1 concentration by the IgG2a concentration of each mouse. Antibody results are expressed as geometric
group means (mg/ml+data set variance). Statistical significance was assessed using Mann Whitney U test with **p,0.005; *p,0.05 and N.A. = not
applicable.
doi:10.1371/journal.pone.0067412.g003
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Figure 4. Prime/boost vaccination route impacts vaginal mucosal antibody levels and antigen reactive B cells. Mucosal antigen-
specific IgG (a) and IgA (b) titres from vaginal mucosal lavage were assessed (n = 8 per group) at the end of the study (week 13). Antibody results are
expressed as group means (mg/ml+SEM). At the end of the study, antibody secreting IgG (c) and IgA (d) cells were obtained from excised spleens and
plated at a density of 56106 cells/ml in a commercial IgG or IgA ELISPOT plate. Samples were stimulated with 5 mg/ml gp140 antigen for 16 h and
developed as per the manufacturer’s instructions. Results represent group means (n = 8 mice per group) of IgG or IgA Spot Forming Units (SFU)/
million antigen stimulated cells (+ SEM). Antigen-specific IgA secreting B cells from enzymatically digested and mechanically disrupted vaginal tissue
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the IN (**p=0.0022) and SL (*p=0.026) vaccination regimens on
day 4 post infection respectively. No protection was seen after
I.Vag vaccination (Fig. 5d). As the mucosal prime-boost
vaccination strategy was designed to prevent infection, no further
monitoring of weight loss was assessed past day 4; a time point
previously established to distinguish statistical significance between
protected and unprotected controls. Moreover, both the IN
(433.3 SFU/million cells, **p=0.0043) and SL (141.3 SFU/
million cells, **p=0.0087) DNA prime boost vaccination regimen
resulted in significantly elevated IFN-c T cell responses compared
to the unimmunised controls (Fig. 5e).
Discussion
It is anticipated that mucosally applied vaccination strategies
will be superior to conventional parenteral based vaccination
modalities for providing protective local mucosal responses against
invading pathogens [18]. Furthermore, the concept of mucosal
linkage allows for discrete but linked mucosal routes of immuni-
sation to elicit protective local immune responses through the
selective recruitment and homing of activated immune cells
[19,20]. Previous studies utilising HIV-1 gp140 antigens have
demonstrated their limited immunogenicity upon injection [21],
while we and others have shown unadjuvanted trimeric HIV-1
CN54gp140 antigen to be ineffective at generating antigen-specific
responses when applied topically to the vagina and nasal mucosa
[22,23]. Therefore in the current study we explored the potential
of mucosal DNA vaccination to improve the local immune
priming of vaccine antigen-specific responses. Moreover, we
compared and contrasted the humoral immune responses elicited
following DNA prime and protein boost immunisation regimens at
different target mucosal surfaces. While a number of DNA prime
protein boost vaccination strategies have been published using a
range of HIV-1 antigen constructs, the majority involve the
parenteral delivery of the DNA prime or viral vector component
[24–27]. To our knowledge, few studies have directly compared
the intranasal, vaginal and sublingual routes for their abilities to be
immunologically primed by a gp140 expressing plasmid. This
makes associations with other studies difficult. Certainly, of the few
studies employing the mucosal route of delivery for both the prime
and boost components, there is agreement that the plasmid DNA
facilitates augmented immune responses. For instance, the use of
DNA-VLP prime boost immunisation has been shown to
significantly increase serum anti-env antibody titres, T cell
proliferation and IFN-c production when compared to VLP-
VLP prime boost vaccine regimens [28].
In this study we found that the DNA prime protein boost
vaccination regimen applied to the nasal mucosa elicited both
antigen-specific IgG and IgA and antigen-specific B cells in
systemic and mucosal compartments. This contrasted to the
vagina as a site of inoculation, which only generated serological
IgA, mucosal IgA and a 6-fold increase in the numbers of antigen-
specific IgA producing B cells in the vagina but none in the spleen.
Finally, we found that sublingual delivery resulted in mucosal IgG
and low level IgG and IgA B cell responses in spleen along with a
biased IgG2a profile but no increase in antigen-specific vaginal B
cell numbers. Collectively these results allow us to conclude that
nasal immunisation is superior to the other forms of mucosal
delivery tested; for generating humoral responses in the mouse
model. However, if local responses in the vagina are required, then
these studies show that vaginal delivery can cause greater local
recruitment of antigen-specific B cells compared to IN and SL
regimens.
In the mouse, the ability of the vaginal epithelium to participate
in the luminal transcytosis of IgA has been shown to be dependent
on the stage of the estrus cycle. Furthermore the expression of
pIgR was previously found to be increased in Depo-treated mice
[29]. Thus the observed difference between the IN and I.Vag
mucosal IgA concentrations after DNA prime-boost vaccination
may be due systemic dissemination. The observed increase in
lymphocyte recruitment to the vagina is supported by previous
observations by Marks et al., 2011 [30]. Here they used adoptively
transferred OVA-specific TCR transgenic T cells and showed that
I.Vag immunisation using OVA conjugated to the potent CT
adjuvant generated T cell recruitment to the vagina and enhanced
CD4+ T cell responses in the draining lymph nodes. In our study,
no T cell responses were assayed and the measured breadth of the
B cell humoral response after topical vaginal vaccination is
restricted to antigen-specific IgA and does not encompass IgG. In
addition, IgA was seen only after multiple protein boosts.
Using an influenza challenge system, we were able to assess the
effective functionality of plasmid DNA mediated priming through
mucosal surfaces. As expected, the data shows that effective
immune priming could be achieved after IN DNA vaccination,
resulting in detectable antibody levels upon adjuvant-free protein
boosting. Moreover, this data suggests that the SL route can also
be utilised as a delivery site for plasmid DNA prime vaccination.
Previous studies by Song et al., 2008 has shown that application of
inactivated influenza or live A/PR/8 virus to the SL space can
convey protection against challenge infection [31]. Critically they
show that administration of substances via the SL route does not
lead to trafficking of vaccine components to the CNS, making this
route of administration appear safer when compared to IN. While
we observed elevated antibody levels in serum after SL vaccination
with DNA polyplexes and protein boost, this was not statistically
significant. However, as multiple protein SL immunisations in the
absence of DNA priming is ineffective against viral challenge (data
not shown), it is highly likely that additional protein boosts to the
DNA priming protocol would have improved upon this. Critically,
after SL vaccination, there was an observed partial protection
against influenza challenge in these animals with a statistically
relevant reduction in infection-associated weight loss. This has
important implications for the vaccine field as this data suggests
that, not only is it possible to prime immune responses via the
intranasal route but, it may also be possible to successfully deliver
DNA and prime immune responses via the sublingual route. While
low volume vaccine formulations are preferable to prime specific
tissues and avoid formulation dissemination, it should be
mentioned that within this study we used a 30 ml vaccine
formulation as opposed to the initial 15 ml volumes. This was
done to compensate for DNA-PEI complex precipitation. There-
fore, as volumes greater than 20 ml have the opportunity to 1)
prime the lower respiratory tract as well as the NALT after IN
administration, 2) increase the chance of swallowing after SL
administration and 3) increase the chance of leakage after vaginal
administration, this should be taken into account.
Taken together these findings may have important implications
for vaccine design where protection of at-risk mucosal tissues is
(e) were determined using a direct ELISPOT assay at the end of the study (week 13). Results represent pooled samples and are expressed as fold
increase in SFU/million antigen stimulated cells (+ SEM) as compared to negative controls. Statistical significance was assessed using Mann Whitney U
test with ***p,0.0005, **p,0.005 and *p,0.05. Data are representative of two independent experiments or are pooled from two experiments.
doi:10.1371/journal.pone.0067412.g004
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Figure 5. Nasal and sublingual vaccination results in protection against Influenza challenge infection. Serum-antigen-specific IgG
antibody responses (n = 6 per group) were recorded one week after 3 DNA primes and a single HA boost (a, b and c). Specifically, a 20 mg/30 ml
volume of plasmid DNA was administered three times, every two weeks, before a single 10 mg/30 ml HA protein boost. Serum anti-HA antibody
concentrations are expressed as group means (ng/ml+SEM). One week after the final vaccination, mice were infected with 5HA units of Influenza X-
31 in 100 ml (d). Body weights for DNA prime protein boost vaccinations (2) and single protein vaccination (2) groups are expressed as a mean
percentage of total weight relative to day 0. Mean IFN-c T cell responses were assessed on day 4 post infection using a commercial ELISPOT assay
coated with HA protein (e). Results represent the means of (n = 6) IFN-c SFU/million splenocytes on day 4 post-infection. Statistical significance was
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desired. While these current studies have been conducted in the
murine model, future studies will need to be carried out to evaluate
the different routes of mucosal vaccination in the context of DNA
prime, recombinant protein boost vaccine strategies in humans.
Furthermore, it would be interesting to see how concomitant
delivery of prime-boost vaccination strategies to multiple different
mucosal tissues might influence immune responses. This could
have a significant impact for prophylactic disease prevention of at
risk tissues, such as the mucosa; where heightened local mucosal B
cell and antibody responses may be beneficial.
Supporting Information
Figure S1 Vaccination schedule for study 1. Intranasal
DNA prime – protein boost vaccination studies were carried out
on female BALB/c mice. Mice (n = 6 per group) were immunised
at two week intervals (red arrows) with a single gp140 DNA prime
vaccination (20 mg) followed by triple gp140 recombinant protein
boost (20 mg) vaccinations. Blood sampling for antigen-specific
antibody determination was carried out as indicated.
(TIF)
Figure S2 Vaccination schedule for study 2. Intranasal,
sublingual and intravaginal immunisation using DNA prime –
protein boost vaccination regimens were carried out on medrox-
yprogesterone treated female BALB/c mice. Mice (n = 6 per
group) were immunised at two week intervals (red arrows) with a
triple DNA prime vaccination (20 mg) regimen followed by triple
recombinant gp140 protein boost (20 mg) vaccinations. Blood
sampling for antigen-specific antibody determination was carried
out as indicated.
(TIF)
Figure S3 Vaccination schedule for Influenza challenge
study 3. Intranasal DNA prime – protein boost vaccination
studies were carried out on female BALB/c mice. Mice (n = 6 per
group) were immunised at two week intervals (red arrows) with a
triple DNA prime vaccination (20 mg) followed by a single
recombinant HA protein boost (10 mg) vaccination. Blood
sampling for antigen-specific antibody determination was carried
out as indicated.
(TIF)
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